No connection

Search Results

PBYI vs SLN

PBYI
Puma Biotechnology, Inc.
BEARISH
Price
$7.24
Market Cap
$368.3M
Sector
Healthcare
AI Confidence
85%
SLN
Silence Therapeutics plc
BEARISH
Price
$7.53
Market Cap
$355.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
PBYI
11.87
SLN
--
Forward P/E
PBYI
11.14
SLN
-10.46
P/B Ratio
PBYI
2.8
SLN
5.71
P/S Ratio
PBYI
1.61
SLN
636.26
EV/EBITDA
PBYI
6.31
SLN
-12.02

Profitability

Gross Margin
PBYI
74.53%
SLN
61.54%
Operating Margin
PBYI
22.67%
SLN
-37150.0%
Profit Margin
PBYI
13.62%
SLN
0.0%
ROE
PBYI
27.97%
SLN
-90.27%
ROA
PBYI
10.85%
SLN
-30.79%

Growth

Revenue Growth
PBYI
27.7%
SLN
-99.9%
Earnings Growth
PBYI
-34.4%
SLN
--

Financial Health

Debt/Equity
PBYI
0.22
SLN
0.0
Current Ratio
PBYI
2.0
SLN
8.72
Quick Ratio
PBYI
1.86
SLN
8.06

Dividends

Dividend Yield
PBYI
--
SLN
--
Payout Ratio
PBYI
0.0%
SLN
0.0%

AI Verdict

PBYI BEARISH

PBYI presents a stable Piotroski F-Score of 4/9, but the stock is currently trading at a significant premium to its Graham Number ($5.96) and Intrinsic Value ($4.27). While the company maintains impressive gross margins (74.53%) and a strong ROE (27.97%), these are offset by a concerning -34.4% YoY earnings growth. With a technical trend score of 10/100 and an analyst target price of $5.00, the current price of $7.24 appears fundamentally overextended. Bearish insider activity from the CEO and CFO further suggests a lack of confidence in near-term upside.

Strengths
High gross profit margins of 74.53%
Strong Return on Equity (ROE) at 27.97%
Low leverage with a Debt/Equity ratio of 0.22
Risks
Current price ($7.24) is significantly higher than Intrinsic Value ($4.27)
Negative YoY earnings growth of -34.4% despite revenue growth
Strong bearish insider sentiment with sales from CEO, CFO, and Directors
SLN BEARISH

SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.

Strengths
High current ratio (8.72) providing short-term liquidity
Zero debt (Debt/Equity 0.00) reducing insolvency risk from leverage
Positive gross margin (61.54%) suggesting potential for product viability
Risks
Near-total collapse of revenue (-99.90% YoY)
Extreme operational inefficiency (Operating Margin -37,150%)
Critical financial health score (Piotroski 1/9)

Compare Another Pair

PBYI vs SLN: Head-to-Head Comparison

This page compares Puma Biotechnology, Inc. (PBYI) and Silence Therapeutics plc (SLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile